Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study to assess efficacy and safety of metronomic oral Idarubicin in patients with hepatocarcinoma at intermediate-advanced stage after failure or intolerance to Sorafenib and Regorafenib

X
Trial Profile

Phase II study to assess efficacy and safety of metronomic oral Idarubicin in patients with hepatocarcinoma at intermediate-advanced stage after failure or intolerance to Sorafenib and Regorafenib

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idarubicin (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms Metro IDA
  • Most Recent Events

    • 10 Mar 2022 Status changed from recruiting to discontinued.
    • 06 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top